{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:28:37Z","timestamp":1769354917278,"version":"3.49.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"L & T Charitable Foundation Ltd"},{"name":"Hong Kong Concrete Co. Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mycophenolate has been shown to be effective in glomerular disease. However, the role of mycophenolate in the first-line treatment of adult-onset idiopathic minimal change disease (MCD) has not been systematically studied in a randomized fashion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To evaluate the therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for MCNS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A prospective, open-label, randomized clinical trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty adult patients with biopsy proven MCD were recruited and randomly assigned to receive either enteric-coated Mycophenolate Sodium (EC-MPS) plus low-dose prednisolone (Group 1: Prednisolone 0.25 mg\/kg\/day, n = 10) or standard-dose prednisolone (Group 2: Prednisolone 1 mg\/kg\/day, n = 10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 24 weeks of therapy, eight patients in Group 1 vs. seven of patients in Group 2 achieved complete remission (P = 0.606). Both groups showed a significant reduction of urine protein excretion (P &amp;lt; 0.05) and increased serum albumin (P &amp;lt; 0.001) vs. baseline levels. However, no significant between-group differences were demonstrated. The relapse rate was also similar in both groups. Both treatment regimens were well tolerated but there were more patient reported adverse effects in the standard-dose prednisolone group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>EC-MPS plus low-dose prednisolone is non-inferior to standard-dose prednisolone therapy in inducing clinical remission and preventing relapse in adult-onset idiopathic MCD and is associated with better tolerability and less adverse effects. This trial is registered with the ClinicalTrials.gov number NCT01185197.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcz297","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T20:09:18Z","timestamp":1574539758000},"page":"399-403","source":"Crossref","is-referenced-by-count":4,"title":["Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease"],"prefix":"10.1093","volume":"113","author":[{"given":"M K M","family":"Ma","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Y H","family":"Yap","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C L","family":"Li","sequence":"first","affiliation":[{"name":"Renal Department, Centro Hospitalar Conde de S\u00e3o Janu\u00e1rio, Macao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M M Y","family":"Mok","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G C W","family":"Chan","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L P Y","family":"Kwan","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K N","family":"Lai","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":false,"given":"S C W","family":"Tang","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"2020060803543607300_hcz297-B1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N Engl J Med"},{"key":"2020060803543607300_hcz297-B2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/kisup.2012.18","article-title":"Chapter 5: minimal-change disease in adults","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2020060803543607300_hcz297-B3","first-page":"71","volume-title":"Integrated Systematic Nephrology","author":"Tang","year":"2005"},{"key":"2020060803543607300_hcz297-B4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","article-title":"Mycophenolate mofetil treatment for primary glomerular diseases","volume":"61","author":"Choi","year":"2002","journal-title":"Kidney Int"},{"key":"2020060803543607300_hcz297-B5","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","article-title":"Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome","volume":"23","author":"Dorresteijn","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"2020060803543607300_hcz297-B6","first-page":"268","article-title":"Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center","volume":"72","author":"Fujinaga","year":"2009","journal-title":"Clin Nephrol"},{"key":"2020060803543607300_hcz297-B7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.ki.5002653","article-title":"Dal Canton A. Mycophenolate mofetil in primary glomerulopathies","volume":"73","author":"Sepe","year":"2008","journal-title":"Kidney Int"},{"key":"2020060803543607300_hcz297-B8","first-page":"127","article-title":"The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease","volume":"21","author":"Siu","year":"2008","journal-title":"J Nephrol"},{"key":"2020060803543607300_hcz297-B9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.clinthera.2009.04.011","article-title":"A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study","volume":"31","author":"Li","year":"2009","journal-title":"Clin Ther"},{"key":"2020060803543607300_hcz297-B10","doi-asserted-by":"crossref","first-page":"e024882","DOI":"10.1136\/bmjopen-2018-024882","article-title":"Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study)","volume":"8","author":"Ehren","year":"2018","journal-title":"BMJ Open"},{"key":"2020060803543607300_hcz297-B11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","article-title":"Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses","volume":"18","author":"Tse","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2020060803543607300_hcz297-B12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"2020060803543607300_hcz297-B13","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","article-title":"Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome","volume":"22","author":"Afzal","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2020060803543607300_hcz297-B14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00467-003-1175-4","article-title":"Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome","volume":"18","author":"Barletta","year":"2003","journal-title":"Pediatr Nephrol"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcz297\/31199277\/hcz297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/6\/399\/33356369\/hcz297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/6\/399\/33356369\/hcz297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T07:54:51Z","timestamp":1591602891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/113\/6\/399\/5643763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,11,26]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcz297","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2019,11,26]]}}}